Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: A 6-year follow-up study

Hsiu Chen Lin, Baxter H. Kachingwe, Hsiu Li Lin, Hui Wen Cheng, Yow Shieng Uang, Li Hsuan Wang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

STUDY OBJECTIVE To explore the effects of metformin dose on cancer risk reduction in patients with type 2 diabetes. DESIGN Population-based cohort study. DATA SOURCE National Health Insurance program Longitudinal Health Insurance Database. PATIENTS A total of 65,754 age- and gender-matched patients without diabetes and no previous cancer diagnosis were extracted from the database. MEASUREMENTS AND MAIN RESULTS We compared cancer risk among the subjects who had no diabetes, had type 2 diabetes but were not on diabetes drugs, used metformin only, used antidiabetic drugs other than metformin, or used metformin in combination with other antidiabetic drugs. Our results revealed dose-dependent effects of metformin on cancer risk and cancer onset times. A significant decrease in cancer risk was found in the monotherapy group who received more than 360 defined daily doses (DDDs) of metformin (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.24-0.66). The greatest decrease in cancer risk was observed in patients who took more than 1080 DDDs (HR 0.27, 95% CI 0.09-0.84). Significantly greater dose-dependent effects were seen in patients who used metformin in combination with other antidiabetic drugs. CONCLUSION The magnitude of cancer risk reduction and prolonged cancer onset times produced by metformin in patients with type 2 diabetes depended on the dose of metformin, regardless of whether metformin was used alone or combined with other antidiabetic drugs.

Original languageEnglish
Pages (from-to)36-45
Number of pages10
JournalPharmacotherapy
Volume34
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Metformin
Risk Reduction Behavior
Type 2 Diabetes Mellitus
Neoplasms
Hypoglycemic Agents
National Health Programs
Databases
Confidence Intervals
Health Insurance
Cohort Studies

Keywords

  • Cancer
  • Dose effect
  • Metformin
  • Risk
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus : A 6-year follow-up study. / Lin, Hsiu Chen; Kachingwe, Baxter H.; Lin, Hsiu Li; Cheng, Hui Wen; Uang, Yow Shieng; Wang, Li Hsuan.

In: Pharmacotherapy, Vol. 34, No. 1, 2014, p. 36-45.

Research output: Contribution to journalArticle

@article{e8fcf97726354f98ae7c256e6af7c676,
title = "Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: A 6-year follow-up study",
abstract = "STUDY OBJECTIVE To explore the effects of metformin dose on cancer risk reduction in patients with type 2 diabetes. DESIGN Population-based cohort study. DATA SOURCE National Health Insurance program Longitudinal Health Insurance Database. PATIENTS A total of 65,754 age- and gender-matched patients without diabetes and no previous cancer diagnosis were extracted from the database. MEASUREMENTS AND MAIN RESULTS We compared cancer risk among the subjects who had no diabetes, had type 2 diabetes but were not on diabetes drugs, used metformin only, used antidiabetic drugs other than metformin, or used metformin in combination with other antidiabetic drugs. Our results revealed dose-dependent effects of metformin on cancer risk and cancer onset times. A significant decrease in cancer risk was found in the monotherapy group who received more than 360 defined daily doses (DDDs) of metformin (hazard ratio [HR] 0.40, 95{\%} confidence interval [CI] 0.24-0.66). The greatest decrease in cancer risk was observed in patients who took more than 1080 DDDs (HR 0.27, 95{\%} CI 0.09-0.84). Significantly greater dose-dependent effects were seen in patients who used metformin in combination with other antidiabetic drugs. CONCLUSION The magnitude of cancer risk reduction and prolonged cancer onset times produced by metformin in patients with type 2 diabetes depended on the dose of metformin, regardless of whether metformin was used alone or combined with other antidiabetic drugs.",
keywords = "Cancer, Dose effect, Metformin, Risk, Type 2 diabetes",
author = "Lin, {Hsiu Chen} and Kachingwe, {Baxter H.} and Lin, {Hsiu Li} and Cheng, {Hui Wen} and Uang, {Yow Shieng} and Wang, {Li Hsuan}",
year = "2014",
doi = "10.1002/phar.1334",
language = "English",
volume = "34",
pages = "36--45",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus

T2 - A 6-year follow-up study

AU - Lin, Hsiu Chen

AU - Kachingwe, Baxter H.

AU - Lin, Hsiu Li

AU - Cheng, Hui Wen

AU - Uang, Yow Shieng

AU - Wang, Li Hsuan

PY - 2014

Y1 - 2014

N2 - STUDY OBJECTIVE To explore the effects of metformin dose on cancer risk reduction in patients with type 2 diabetes. DESIGN Population-based cohort study. DATA SOURCE National Health Insurance program Longitudinal Health Insurance Database. PATIENTS A total of 65,754 age- and gender-matched patients without diabetes and no previous cancer diagnosis were extracted from the database. MEASUREMENTS AND MAIN RESULTS We compared cancer risk among the subjects who had no diabetes, had type 2 diabetes but were not on diabetes drugs, used metformin only, used antidiabetic drugs other than metformin, or used metformin in combination with other antidiabetic drugs. Our results revealed dose-dependent effects of metformin on cancer risk and cancer onset times. A significant decrease in cancer risk was found in the monotherapy group who received more than 360 defined daily doses (DDDs) of metformin (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.24-0.66). The greatest decrease in cancer risk was observed in patients who took more than 1080 DDDs (HR 0.27, 95% CI 0.09-0.84). Significantly greater dose-dependent effects were seen in patients who used metformin in combination with other antidiabetic drugs. CONCLUSION The magnitude of cancer risk reduction and prolonged cancer onset times produced by metformin in patients with type 2 diabetes depended on the dose of metformin, regardless of whether metformin was used alone or combined with other antidiabetic drugs.

AB - STUDY OBJECTIVE To explore the effects of metformin dose on cancer risk reduction in patients with type 2 diabetes. DESIGN Population-based cohort study. DATA SOURCE National Health Insurance program Longitudinal Health Insurance Database. PATIENTS A total of 65,754 age- and gender-matched patients without diabetes and no previous cancer diagnosis were extracted from the database. MEASUREMENTS AND MAIN RESULTS We compared cancer risk among the subjects who had no diabetes, had type 2 diabetes but were not on diabetes drugs, used metformin only, used antidiabetic drugs other than metformin, or used metformin in combination with other antidiabetic drugs. Our results revealed dose-dependent effects of metformin on cancer risk and cancer onset times. A significant decrease in cancer risk was found in the monotherapy group who received more than 360 defined daily doses (DDDs) of metformin (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.24-0.66). The greatest decrease in cancer risk was observed in patients who took more than 1080 DDDs (HR 0.27, 95% CI 0.09-0.84). Significantly greater dose-dependent effects were seen in patients who used metformin in combination with other antidiabetic drugs. CONCLUSION The magnitude of cancer risk reduction and prolonged cancer onset times produced by metformin in patients with type 2 diabetes depended on the dose of metformin, regardless of whether metformin was used alone or combined with other antidiabetic drugs.

KW - Cancer

KW - Dose effect

KW - Metformin

KW - Risk

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84898048917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898048917&partnerID=8YFLogxK

U2 - 10.1002/phar.1334

DO - 10.1002/phar.1334

M3 - Article

C2 - 23864581

AN - SCOPUS:84898048917

VL - 34

SP - 36

EP - 45

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -